ULTRAGENYX PHARMACEUTICAL INC. Deferred Income Tax Expense (Benefit)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Deferred Income Tax Expense (Benefit) of -$1.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. deferred income tax expense (benefit) for fiscal 2024 was -$1.00M.
- ULTRAGENYX PHARMACEUTICAL INC. deferred income tax expense (benefit) for fiscal 2023 was -$2.00M, a 221.95% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. deferred income tax expense (benefit) for fiscal 2022 was $1.64M.
- ULTRAGENYX PHARMACEUTICAL INC. deferred income tax expense (benefit) for fiscal 2019 was $2.14M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-12-31 | -$1.00M 10-K · filed 2026-02-18 | $1.37M 10-K · filed 2025-02-19 |
| 2023-12-31 | -$2.00M 10-K · filed 2026-02-18 | $1.76M 10-K · filed 2024-02-21 |
| 2022-12-31 | $1.64M 10-K · filed 2025-02-19 | -$1.64M 10-K · filed 2023-02-17 |
| 2019-12-31 | $2.14M 10-K · filed 2022-02-15 | |
| 2017-12-31 | -$16.25M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |